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ABSTRACT 
Shingles is a prevalent disease within the overall population, and incidence in North America 
continues to increase.  Shingles is commonly found in older adults 60 years of age and older and 
can recur two or three times.  Shingrix was released in 2017 as a recombinant vaccine for 
prevention of shingles.  Despite its benefits, this vaccine has not been recommended by many 
prescribing providers.  Research has shown that an effective education program improves 
attitudes and misconceptions related to vaccines and can increase prescribing rates.  An 
education program was created to share with prescribing providers to improve overall knowledge 
and recommendation rates for the vaccine.  This formal education program was designed for 
prescribing providers for review in a 30-minute seminar.  To determine overall effectiveness, the 
program was piloted in a primary care office setting in Central Virginia.  The program was found 
to increase overall knowledge and appeared to increase the likelihood of recommendation.  This 
evidence-based practice project was consistent with established research indicating that when a 
prescribing provider is informed about a vaccine, he or she is more likely to discuss it with 
patients.  Patients consider their prescribing provider’s opinion seriously when making decisions 
about vaccines, including Shingrix.   
Keywords: chickenpox, herpes zoster, immunization, recombinant zoster vaccine, 
shingles, Shingrix vaccination, varicella zoster virus, Zostavax, vaccine hesitancy, vaccine 
education 
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SECTION ONE: INTRODUCTION 
Shingles is a prevalent disease that is caused by the herpes zoster virus (Bresse et al., 
2013).  This condition typically presents with symptoms of blistering rash, localized pain, 
numbness, localized burning, and itching.  Patients may also present with headache, nausea, and 
chills (Bresse et al., 2013).  This disease occurs in 2 to 4.6 cases per 1,000 individuals in patients 
ages 50–79 and 10 to 12.8 cases per 1,000 individuals in patients 80 years and older.  
Postherpetic neuralgia (PHN) is a common complication of shingles.  Among those who are 
diagnosed with shingles, 20% of patients 60 to 65 years of age and 30% of patients older than 80 
years of age are diagnosed with PHN.  The Shingrix vaccine is a new, attenuated (weaker) 
immunization that offers protection against the shingles virus (Chan et al., 2018).  Prior to Food 
and Drug Administration approval on October 23, 2017, the live vaccine Zostavax was the best 
prevention against shingles (GlaxoSmithKline, 2017).  Shingrix is more than 90% effective in 
preventing shingles and PNH in all populations and poses less risk than the live immunization, 
Zostavax (Bharucha, Ming, & Breuer, 2017).   
This vaccine is a priority for providers to be educated about because it was released for 
public use less than two years ago (GlaxoSmithKline, 2017).  Due to its recent release, many 
patients are not aware of the immunization.  In addition, providers are less likely to recommend 
the vaccine because of time constraints during wellness visits.  Providers may not have 
previously researched the vaccine and therefore may not feel comfortable recommending it.  
Another issue that may result in provider hesitancy to recommend the Shingrix vaccine is the 
cost.  According to GoodRx (2018), the average price of the Shingrix vaccine is approximately 
$184.71.  The vaccination is given in a two-dose series two to six months apart, and the total cost 
of the Shingrix vaccine is $381.67 (GoodRx, 2018).  Many insurance companies were previously 
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not covering the vaccine, but recent changes have led to coverage by almost all commercial 
insurances (Centers for Disease Control [CDC], 2018).    
  Although this vaccine is effective at protecting individuals from disease, compliance 
rates for Shingrix are low.  Since the Shingrix immunization was newly released in 2017, it is 
possible that patients are unaware that they can have greater protection against the shingles virus.  
The purpose of this scholarly project was to educate health care providers on the benefits of the 
new Shingrix vaccine and increase vaccine recommendations to their patients.   
Background 
 The prevalence of shingles is approximately 30% of the population, and 10% of these 
individuals will develop PHN (Friesen, Chateau, Falk, Alessi-Severini, & Bugden, 2017).  The 
incidence in North America is between three and five people per 1,000 yearly (Kawai, 
Gebremeskel, & Acosta, 2014).  The incidence for patients age 60 and older is 10 per 1,000 
individuals.  Herpes zoster can also recur in second or third episodes, but the incidence for these 
occurrences is unknown (CDC, 2018).  One to four percent of individuals are hospitalized related 
to complications, and 96 deaths per year have herpes zoster designated as the cause.  Herpes 
zoster rates have been increasing gradually over time (CDC, 2018).  While a specific factor has 
not been directly linked to the increase, a consideration is the introduction of the varicella 
(chickenpox) vaccine.  Some cohorts may experience an increase in shingles due to the varicella 
vaccine (Rafferty, McDonald, Qian, Osgood, & Doroshenko, 2018).  However, most countries 
have indicated an increase regardless of varicella immunization compliance (Rafferty et al., 
2018).   
 Varicella zoster virus (VZV) can be spread through direct contact when an infected 
individual has active lesions.  In addition, hospital protocol requires airborne precautions for 
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immunocompromised individuals and disseminated infections to prevent airborne transmission.  
The lesions are infectious until they are dry and crusted over (CDC, 2018).  This allows 
transmission to individuals without previous exposure to VZV to become infected.  These 
individuals can present with a varicella outbreak following this exposure, which then can emerge 
as herpes zoster during reactivation.  Individuals who have been infected with VZV or who have 
been vaccinated for varicella could develop this condition (CDC, 2018).  Those who have active 
lesions are advised to limit contact with others until they are dry to prevent transmission.   
 The most significant risk factor for shingles is previous exposure to VZV.  Currently in 
the United States, 99.5% of individuals 40 years of age and older have been exposed to the virus, 
making them more likely to develop shingles (CDC, 2018).  Risk also increases as immunity to 
the virus declines and could be related to aging, immunodeficiency, immunosuppression, or 
current medications (CDC, 2018).  Immunosuppression and immunodeficiency may occur due to 
leukemia, lymphoma, a bone marrow transplant, HIV, medications including steroids, or 
chemotherapy.  An individual over the age of 50 is more likely to develop shingles, and risk 
continues to increase with aging.  Studies have shown that women are more likely to develop this 
condition than men.  In addition, individuals who are Caucasian are more likely to develop 
herpes zoster than those who are African American (CDC, 2018).   
 When VZV initially enters the body, it has an impact on the sensory neurons and skin.  
The virus then becomes latent in the neuronal ganglia and stays in the ganglia permanently 
(Friesen et al., 2017).  The virus typically reactivates in a single ganglion, classically causing 
moderate to severe pain and a maculopapular rash that follows along the dermatome (Friesen et 
al., 2017).  The rash typically appears with vesicles over the course of three to five days and then 
begins to dry and crust over within two to four weeks (CDC, 2018).  The rash may also present 
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in a second nearby dermatome, and the most common area of appearance is the thoracic 
dermatome (CDC, 2018).  Typically, the rash does not cross midline; however, some individuals 
may develop a more diffuse rash impacting three dermatomes or more.  In addition to pain, a 
patient may complain of itchiness or a tingly sensation at the site.  Patients may also admit 
generalized malaise, headache, and photophobia during the prodrome of the virus (CDC, 2018).   
 A mild complication of scarring or darkened pigmentation at the area of the rash may 
occur (CDC, 2018).  The most common complication, which impacts 10% of individuals who 
are diagnosed with herpes zoster, is PHN (Friesen et al., 2017).  PHN is a pain syndrome that 
persists after herpes zoster has resolved due to inflammation or virus-induced nerve damage 
(Friesen et al, 2017).  Other complications that may occur include ophthalmic involvement 
accompanied by acute or chronic ocular sequelae, bacterial infection of lesions, cranial and 
peripheral nerve palsies, and, in severe cases, visceral involvement (CDC, 2018).   
 Prior to the introduction of the Shingrix vaccine, Zostavax was recommended by the 
CDC for protection against herpes zoster (CDC, 2018).  It is administered to patients 50 years of 
age and older (MerckVaccines, 2018).  It contains a live-attenuated VZV, or a weaker version of 
the virus, to expose the patient’s body to the virus and result in the manufacturing of specific 
antibodies.  It is given as a single dose subcutaneously.  It has a large side effect profile and 
cannot be given to those who are pregnant or immunocompromised (MerckVaccines, 2018).   
Shingrix is a recombinant vaccine that is given intramuscularly in two doses two to six 
months apart (Deshpande, 2018).  Each dose is a 0.5 mL injection (Deshpande, 2018).  Patients 
that are recommended to receive the vaccine are older than 50 years of age (CDC, 2018).  
Patients who have had shingles in the past are encouraged to receive the vaccination as soon as 
possible, as long as the acute infection has resolved.  One dose allows protection for life.  
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Patients should still receive Shingrix even if they have received Zostavax in the past.  Common 
side effects associated with the immunization include redness and edema at the injection site 
(CDC, 2018).  Other side effects that are associated with Shingrix include fatigue, muscle aches, 
headache, chills, fever, stomach pain or nausea.  The vaccine should not be administered if the 
patient has ever had a severe allergic reaction such as anaphylaxis to a component of the vaccine 
or the initial dose of Shingrix.  Severe allergic reactions are uncommon and may present as 
symptoms including hives, facial swelling, increased heart rate, dizziness, and weakness (CDC, 
2018).   
Problem Statement 
According to the CDC (2018), Shingrix is more than 90% effective at preventing shingles 
and long-term nerve pain.  Despite the promising benefits of the new vaccine, many health care 
providers are failing to routinely recommend vaccines to their patients.  Patients have stated if 
their provider discussed the immunization with them, they would be more likely to receive it 
(Ridda, MacIntyre, & Lindley, 2009).  Targeted interventions focusing on education for medical 
providers with prescriptive authority has led to increased knowledge and improved vaccination 
rates for patients (Ridda et al., 2009).   
Purpose of the Project 
 The purpose of this project was to educate health care providers in a Central Virginia 
internal medicine practice about the new Shingrix vaccine and increase recommendation of the 
vaccine to their patients as a result.  By assessing knowledge before and after the educational 
program, the project coordinator determined the impact of the educational program.  In addition, 
the project coordinator was planning to utilize a pre- and post-education chart review to assess 
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provider recommendations of the vaccine.  Due to unexpected factors, the project coordinator 
was unable to collect this data.   
Clinical Question 
The clinical question was, “Does a Shingrix education program for health care providers 
in a Central Virginia internal medicine practice, vs no formal education program, lead to 
increased overall knowledge for prescribing practitioners and increased recommendations for 
patient vaccination?” 
SECTION TWO: LITERATURE REVIEW 
Search Strategy 
 An extensive search of the literature has been performed using the “search anything” tool 
bar on the Liberty University Library page.  Due to the vast number of articles related to this 
topic, the project coordinator needed to apply filters and search effective keywords (Moran, 
Burson, & Conrad, 2017).  Key words utilized in article searches include provider hesitancy, 
Shingrix, barriers to vaccination, vaccination education for providers, shingles vaccination, and 
immunization education.  Initially, thousands of articles were identified related to the topic of the 
shingles vaccine.  Databases that were subsequently searched include PubMed, Ebsco, PubMed, 
and CINAHL.  Articles that were not published within the last 10 years were omitted by the 
exclusion criteria.  Other specific inclusion and exclusion criteria were not implemented, but 
mainly articles that focused on education for providers about vaccination were chosen.  Articles 
about the Shingrix vaccine and its efficacy were also included to assist in development of the 
educational program and to support the need for providers to recommend the vaccination to their 
patients.  Twenty-four articles were considered to support the implementation of the project.   
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Critical Appraisal 
To ensure that the evidence supports the scholarly project, the articles have been critically 
appraised with Melnyk’s system of hierarchy (University of Michigan Library, 2019).  Articles 
have been analyzed systematically to consider level of evidence, strengths, and weaknesses of 
the evidence.  The study sample, methodology, and results have also been considered (Rousch, 
2015).  The articles have been included that best support this scholarly project.  A table of 
evidence has been included in Appendix A.   
Clinical practice guidelines. A recombinant zoster vaccine (Shingrix) has been available  
in the US since 2017 and is recommended by the CDC and the Advisory Committee on 
Immunization Practices as the preferred shingles vaccine (CDC, 2018).  Shingrix is 
recommended for healthy adults 50 years and older in a two-dose series separated by two to six 
months.  The injection is given in the upper arm.  The two doses of Shingrix are more than 90% 
effective in preventing shingles and PHN.  Patients may receive the Shingrix vaccine even if they 
were previously vaccinated with Zostavax.  Serologic testing to evaluate for the presence of 
previous varicella infection is not indicated prior to vaccination with Shingrix (CDC, 2018). 
Systematic reviews. A systematic review is an analysis of all relevant randomized 
controlled trials (RCTs) and evidence-based clinical guidelines (Hall & Roussel, 2014).  
Systematic reviews were considered to support the need for immunization with the Shingrix 
vaccine.  Bharucha et al. (2017) conducted a systematic review of three different studies which 
focus on the general population, the elderly, and HIV-infected individuals.  The purpose of this 
study was to provide critical appraisal of current evidence regarding Hz/Su, or Shingrix.  The 
results of this study state that “Shingrix is the preferred vaccine, over Zostavax (zoster vaccine 
live), a shingles vaccine in use since 2006” (Bharucha et al., 2017, p. 6).  The study further 
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indicated vaccine efficacy for HZ/Su [Shingrix] for participants over 50 years of age appeared to 
decrease with time (Bharucha et al., 2017) from 96.6% at year 1 to 87.9% at year 4; however, the 
authors concluded that the difference was not statistically significant and longer-term studies are 
needed (Bharucha et al., 2017).  In addition, Bharucha et al. (2017) stated that HZ/Su [Shingrix] 
appears to effectively protect against VZV.  
Paterson et al. (2016) reviewed 185 articles about vaccine hesitancy among health care 
providers and the influence of their knowledge and vaccination behavior on their 
recommendations.  The researchers found that knowledge about vaccines, including their 
efficacy and safety, helped to build health care providers’ confidence in vaccines as well as their 
willingness to recommend vaccines to others (Paterson et al., 2016).  Key recommendations from 
the study included more training or information support on vaccine risks and benefits, more 
patient communication tools for health care providers, and the strengthening of trust between 
health care providers and health authorities (Paterson et al., 2016).  
Sadaf, Richards, Glanz, Salmon, and Omer (2013) conducted a systematic review of 25 
studies to identify interventions for reducing parental vaccine refusal and vaccine hesitancy.  The 
study found there was no evidence to support a specific intervention, but studies consistently 
supported that any type of educational intervention with providers had the ability to increase 
patient immunization (Sadaf et al., 2013).  
Randomized controlled trials (RCTs). An RCT includes a randomized control group 
and randomized experimental group.  The experimental group is exposed to an intervention, and 
impact of the intervention is compared to the control group (Hall & Roussel, 2014).  Articles 
were considered that highlight the effectiveness of the vaccine and determine the impact of 
provider education on vaccination.  In an RCT to determine the effectiveness of the Shingrix 
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vaccine in different age groups (older than 50 years and older than 70 years), the Shingrix 
vaccine was found to be effective for all patients 50 years of age and older and should be 
recommended by providers (Elliott & Chan, 2018).  Another study discussed the efficacy of the 
Shingrix vaccine in which 29,000 subjects were studied globally to determine the effectiveness 
of the vaccine.  The researchers concluded that the vaccine was more than 90% effective in all 
populations (Oakes, 2017).  Another study conducted by GlaxoSmithKline determined that 
Singrix indicated almost 70% efficacy in patients with a stem cell transplant.  The purpose of this 
study was also to identify the effectiveness of the vaccine (“GSK Phase III Study,” 2017).   
In another RCT, Krieger, Castorina, Walls, Weaver, and Ciske (2000) sought to 
determine the impact that additional education can have on vaccination rates.  Participants were 
65 years of age from a senior center.  One group was given additional educational materials on 
the pneumonia vaccine.  When comparing the groups, it was found that immunization rates 
increased as a result of pamphlets and other educational materials distributed to the participants.  
The results indicated that materials provided to patients have an impact on decision making 
related to vaccines, and providers should distribute these materials to their patients (Krieger et 
al., 2000).   
Dubé et al. (2016) studied research network members and health care providers to 
identify the opinion of vaccination experts and health professionals related to the definition, 
scope, causes, and consequences of vaccine hesitancy in Canada.  Two separate surveys were 
administered to randomized groups. All parties were concerned about the decline of vaccination 
rates overall in Canada, but many providers stated that they felt improperly counseled to advise 
vaccine hesitant patients (Dubé et al., 2016).  This study supports the fact that many providers 
feel improperly educated to speak with vaccine-hesitant individuals and that they require further 
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education.  Another RCT was conducted in Japan to determine the impact of the varicella 
vaccine on the occurrence of herpes zoster.  Patients were randomized from 43 clinics in Japan 
and were determined to be at higher risk for shingles related to varicella vaccination and 
prevalence (Toyama & Shiraki, 2018).  This reinforces the need for the shingles vaccine in the 
community.   
Quasi-experimental. Quasi-experimental studies include research from trials that 
include an intervention but are not randomized (Hall & Roussel, 2014).  MacDougall et al. 
(2015) conducted a study with surveys and focus groups to assess knowledge of patients and 
providers related to vaccine preventable disease.  Knowledge related to vaccination was lacking 
in both group, which supports the need for further education for providers overall (MacDougall 
et al., 2015).  
Clark, Jackson, Hodges, Gilliam, and Lane (2015) conducted a quasi-experimental study 
to understand the impact that vaccination education can have on a specific population.  The study 
participants included patients who were at risk for pneumonia and were treated in a presurgical 
center.  Targeted education with flyers was utilized as the intervention, which led to increased 
vaccination rates.  The researchers concluded that if patients are given the appropriate education 
materials by their health care providers, they are more likely to be vaccinated (Clark et al., 2015). 
Jones et al. (2012) conducted a research study to identify factors that influenced parents 
vaccinating their children. For this study, 1,367 parents of children at 1,000 schools across 
Colorado, Massachusetts, and Washington were surveyed.  While patients have increased access 
to health information online and through social media, research confirms that most parents obtain 
and utilize information given to them by medical professionals.  Additionally, the authors 
concluded that if providers prioritize their own vaccination status, they are more willing to 
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encourage their patients to pursue immunization (Jones et al., 2012).  If patients and family view 
vaccinations in a positive light, they are more likely to stay up to date with their own vaccination 
status.  A negative attitude toward vaccination influences patients and families to avoid updating 
their immunization status.  In addition, patients and families with negative attitudes may impact 
the decision of others (Jones et al., 2012).  The authors confirmed that providers need additional 
support and guidance to help educate their patients and their parents.  
Kaplan-Weisman, Waltermaurer, and Crump (2018) conducted a study to determine if 
targeted interventions could increase shingles vaccination rates. A physician provided targeted 
education to 103 participants from a local homeless shelter.  Although the sample size was small, 
the study results indicated that provider understanding of vaccinations and targeted education 
was associated with an increased uptake for vaccination in vulnerable populations (Kaplan-
Weisman et al., 2018).  If the provider feels more prepared to discuss information with their 
patients, education for patients is improved, and therefore vaccination levels are increased.   
Prioli et al. (2018) studied the knowledge base of older adults related to vaccines.  Forty-
five participants in a senior care setting were questioned about vaccines, and knowledge related 
to vaccines was minimal.  The study recommended that education be improved in different 
settings for patients and that providers take on a larger role in ensuring that their patients are 
informed (Prioli et al., 2018).   
Educating new providers such as medical students is also correlated with immunization 
compliance (Schnaith et al., 2018).  Schnaith et al. (2018) provided 101 medical students with an 
educational program catered to them to determine if the program would increase the likelihood 
of the students advising their patients to be vaccinated for human papilloma virus (HPV).  The 
medical students indicated that following the educational program, they were more likely to 
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recommend the HPV vaccine.  The study results indicate that provider education increases the 
likelihood of the provider to recommend the vaccination.  In addition, Suryadevara. Bonville, 
Cibula, and Domachowske (2019) conducted a study to determine if provider, health care staff, 
patient, and parent education about the vaccine and cancer prevention improved compliance with 
the HPV vaccination.  The study included providers and patients from six pediatric offices in 
upstate New York.  The results indicated that vaccination rates for HPV increased by at least 
10% in three practices and at least 5% in three practices.  The study indicated that increased 
provider education about the benefits of vaccination improves overall vaccination rates.  Another 
study by Perkins et al. (2015) tried to identify if an educational program with providers increased 
overall vaccination rates for HPV in pediatric patients.  Educational sessions were conducted 
with the providers who volunteered, and vaccination rates were compared for patients in a 
control group against those whose providers received education.  Girls who were patients of the 
providers in the intervention group were more likely to be vaccinated when compared with girls 
in the control group.  Vaccination rates for the boys stayed about the same when compared with 
the control group.  The study results indicate that more provider education has a positive impact 
on immunization.  Patients of providers who received the education were more likely to be 
vaccinated.  
Reiter, Stubbs, Panozzo, Whitesell, and Brewer (2011) conducted a study to determine 
the impact that education related to vaccination could have on the population.  The sample 
included parents, school staff, and health care staff.  The study results indicated that knowledge 
was improved following targeted education.  This study indicates that education related to 
immunization is important for the community to ensure educated decision making from patients 
and parents (Reiter et al., 2011).  Another study was performed by Leask et al. (2012) to identify 
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different parental attitudes about vaccination and how providers felt would be best to educate 
parents.  The study included 112 articles and then surveyed 103 immunization providers.  Five 
specific parental opinions regarding vaccinations were identified, and providers determined that 
a guiding-style discussion was helpful in talking to parents.  The researchers concluded that there 
were still areas for improvement identified in provider knowledge.  
Real et al. (2017) conducted a study with 45 residents working at the Cincinnati 
Children’s Hospital Medical Center pediatric primary care center to identify the impact of a 
virtual reality educational program related to vaccines.  The intervention group received the 
virtual reality training.  The study results showed a decrease rate of vaccine refusal for the 
patients of the residents that were enrolled in the educational program.  The researchers 
concluded that improved provider education increases providers’ personal knowledge and leads 
to increased vaccination rates (Real et al., 2017).  
Other evidence. Articles from systematic reviews of qualitative studies, quantitative 
studies, and expert opinions are included in this section.  Qualitative studies present 
nonnumerical data correlated with an intervention (Hall & Roussel, 2014).  Expert opinion is 
information presented by a credible source related to the topic (Hall & Roussel, 2014).  An 
article by Bowser (2017) discusses how 15 experts were asked to vote to determine if the 
Shingrix vaccine should be recommended to patients.  The advisory panel voted to recommend 
the Shingrix vaccine over the Zostavax when it was released (Bowser, 2017).  The Shingrix 
vaccine was also supported by the CDC and recommended by experts affiliated with the 
European Union (Zacks Equity Research, 2018).  
Qualitative research indicates the need for increased education for providers and confirms 
the positive impact that it has on patients (Busby, 2018).  In coming to this conclusion, Busby 
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(2018) surveyed residents of British Columbia to examine reasons behind the decreased rates of 
adult vaccination in Canada.  Patients who were vaccinated stated that their health care provider 
recommended it to them.  People that indicated they were not vaccinated felt as though they did 
not have access to all recommended vaccines.  
Loehr and Savoy (2016) discussed methods to encourage vaccine-hesitant patients and 
families and to address their concerns.  The authors stated, “Cultural pressure, misinformation, 
and fear of harm are a few reasons why patients may hesitate to agree to vaccination” (Loehr & 
Savoy, 2016, p. 95).  Models have been proposed on managing vaccine hesitancy, including the 
three Cs (Confidence, Complacency, Convenience), the CASE approach (Corroborate, About 
me, Science, Explain/Advise), and the 3 As (Ask, Acknowledge, Advise).  They concluded that 
research supports the physician’s recommendation as the most important reason a patient accepts 
an immunization (Loehr & Savory, 2016). 
In another qualitative study, Ridda et al. (2009) interviewed elderly patients admitted to 
an 800-bed hospital to identify attitudes toward vaccination and determine why many individuals 
were not immunized.  Patients interviewed stated that one of the reasons that they did not 
consider the vaccination was that their provider did not recommend it.  In addition, patients were 
afraid to develop the illness from the vaccine (Ridda et al., 2009).  The authors concluded that 
providers are not consistently recommending immunizations to their patients according to the 
guidelines.  
A descriptive study was utilized by Jacobson, St. Sauver, and Rutten (2015) to discuss 
the best response to vaccine hesitancy from parents and patients.  The researchers examined 
existing systematic reviews related to this topic.  Findings from the study that were indicated to 
improve vaccination rates include usage of point-of-care reminders, reminder recall, provider 
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positive attitudes about vaccination, and communications and standing orders implemented by 
the physician.  Further studies indicate that vaccinated health care providers are more likely to 
recommend vaccination to others.  The authors stated that primary prevention is best supported 
through education by the patient’s health care provider (Jacobson et al., 2015).  
Synthesis  
Vaccinated health care providers. If providers prioritize their own vaccination status, 
they are more willing to encourage their patients to pursue immunization (Jones et al., 2012).  
The provider can also share with the patient or family that their own immunization status is up to 
date (Jacobson et al., 2015).  If a provider is willing to personally experience the potential side 
effects related to immunization, the patient and family is more likely to trust his or her 
recommendations (Jacobson et al., 2015).  Due to the impact of the provider’s immunization 
status on patient compliance, the prescribing provider should continue to update his or her 
immunization status as necessary.   
Patient attitudes. Another factor that supports vaccination is positive attitudes about 
vaccination by patients (Jacobson et al., 2015).  A recent study was conducted to determine the 
impact of the patient and family’s attitudes on vaccination (Jones et al., 2012).  If patients and 
family view vaccinations in a positive light, they are more likely to stay up to date (Jones et al., 
2012).  A negative attitude toward vaccination influences patients and families to avoid updating 
their immunization status.  In addition, patients and families with negative attitudes may impact 
the decisions of others.   
Vaccine recommendations by health care providers. Patients have stated that if their 
provider discussed an immunization with them, they would be more likely to receive it.  Many 
patients who are not vaccinated state that they did not pursue vaccination because their primary 
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care provider did not discuss it with them (Ridda et al., 2009).  Prioritizing discussions about 
updating vaccination will lead to increased immunization compliance (Clark et al., 2015).  By 
increasing provider education, the project coordinator hoped to improve the number of providers 
that recommend the vaccine to their patients. 
Preparedness of providers. As indicated in the study that focused on education for 
medical students, many providers feel unprepared to recommend a vaccination to their patients 
(Schnaith et al., 2018).  In addition to medical students, many practicing providers may not feel 
educated enough to recommend a vaccine (MacDougall et al., 2015).  The Shingrix vaccine is a 
recently released vaccination and providers may not feel as though they are prepared to discuss 
the risks and benefits with patients and families.  Further education for providers is indicated to 
have a positive impact on immunization (Perkins et al., 2015).   
Interventions to increase vaccine uptake by health care providers. Overall 
immunization rates have been lower when compared to the previous decade, but targeted 
interventions focusing on education for providers has been able to lead to increased knowledge 
and in turn improve vaccination rates for patients (Ridda et al., 2009).  Interventions include a 
focused education program for providers and health promotion education (Perkins et al., 2015).  
All studies that included a specific education program resulted in an increase in vaccination 
rates.   
Conceptual Framework  
The Iowa Model was implemented within this scholarly project and started by analyzing 
the triggers that were present, leading to the creation of the evidence-based practice (EBP) 
project (Hall & Roussel, 2014).  The integral steps that are associated with the Iowa Model in 
research include identifying a trigger, determining organizational priority, formulating a team, 
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examining the evidence, implementing a change into practice, and analyzing the outcomes (Hall 
& Roussel, 2014).  Permission was provided by the University of Iowa Department of Nursing to 
utilize the Iowa Model for this scholarly project; see Appendix B.   
While the other models provide effective policy change, they do not allow for thorough 
evaluation throughout the process.  It is important that a successful screening and education 
program is formulated to ensure that resources are utilized effectively (Hall & Roussel, 2017).  
The Iowa Model allows for evaluation and stepwise change to ensure that any issues with a new 
policy are identified and solved.  
Considering current issues and existing research allows for practice change in a 
procedural fashion (Hall & Roussel, 2014).  There are both problem- and knowledge-based 
triggers identified related to this topic, and the Iowa Model effectively evaluates them and the 
potential opportunities for change.  The knowledge-based trigger was identified when the project 
coordinator was informed about the release of the new vaccine.  The problem-based trigger was 
identified at the practice setting because the project coordinator completed clinicals at the setting 
and determined that the vaccine was not regularly being recommended by providers.  These 
triggers are the reason that this specific change was a focus within this setting (Hall & Roussel, 
2014).   
In addition to the existing triggers, the Iowa Model also considers the drawbacks and 
benefits of a change to the health care organization as a whole (Hall & Roussel, 2014).  This is 
identified in the Iowa Model as determining the organizational priority.  The organizational 
priority is to provide excellent care for life.  By prioritizing education for providers about the 
Shingrix vaccine, the project coordinator is supporting vaccine compliance for patients.  This 
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ensures that the goals of the project coordinator match that of the health care organization before 
the change.   
A team was created in order to support the implementation of the project (Hall & 
Roussel, 2014).  New ideas and changes in a practice setting should be supported by others, as an 
idea that is supported by a group will be more successful.  Support by a group allows for 
effective uptake of a change in practice (Hall & Roussel, 2014).  The project coordinator 
recruited the office manager and a lead physician to support development of the project.   
The project coordinator then considered existing literature (Hall & Roussel, 2014).  If 
research had not been adequate or indicated that a different change would have been more 
favorable, then the project would have been put on hold (Hall & Roussel, 2014).  The project 
coordinator evaluated the literature with an extensive search utilizing the identified key terms.  
This provided reinforcement from other studies that the proposed change would be effective, 
leading to better patient care.  
After the evidence is analyzed, the change can then be tested in practice.  Typically, a 
change is tested as a pilot and occurs on a smaller scale (Hall & Roussel, 2014).  The pilot stage 
is utilized to ensure that the new process is effective.  This EBP project was implemented as a 
pilot because it was integrated into one internal medicine practice.  The practice is a part of a 
care network, and implementing the project in one setting is considered a pilot.  Seven providers 
were included in the pilot stage.  This stage was monitored to determine if adjustments to the 
process should be implemented (Hall & Roussel, 2014).   
After the pilot change in practice occurred, the project coordinator evaluated if the 
change would be effective in the setting and on a larger scale (Hall & Roussel, 2014).  This 
involved the coordinator analyzing the outcomes and considering the information obtained.  
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Thoroughly analyzing the outcomes allowed the project coordinator to confidently support a 
change of practice.  The project coordinator has analyzed the results of the pilot study.   
This concludes the six-step process to effectively integrate a change in practice (Hall & 
Roussel, 2014).  Throughout the project, evaluation and monitoring occurred, and new research 
related to the topic will also be considered.  The main strength of this model is the investigation 
of the research and reevaluation of the change; however, an EBP project that follows the Iowa 
Model typically requires more time and resources when compared to other models.  
Summary 
 Immunization is a priority to support health promotion in patients.  The Shingrix 
vaccination has been recommended by the Food and Drug Administration, and studies have 
continually supported its effectiveness (Bharucha et al., 2017).  Due to its effectiveness, it should 
be recommended for all patients over the age of 50 who are at risk for developing shingles 
(Bharucha et al., 2017).  Considering the development of vaccine hesitancy, providers have the 
responsibility to educate their patients.   
The purpose of this literature review was to identify evidence-based strategies to help 
increase Shingrix vaccinations.  Research indicates that providers feel unprepared and may 
require further education before recommending a new vaccination to others.  Targeted 
educational programs for providers have been portrayed as an effective intervention to improve 
compliance with vaccination.  An educational program focused on the Shingrix vaccine is 
suspected to also have a positive impact.  The literature review supports the need for this 
scholarly project, whose purpose is to educate health care providers in a Central Virginia internal 
medicine about the new Shingrix vaccine and subsequently increase recommendation of the 
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vaccine to patients.  The scholarly project utilized the Iowa Model throughout all the phases of 
the project to implement and evaluate a practice change.   
SECTION THREE: METHODOLOGY  
Design 
The purpose of this scholarly project was to determine if the implementation of a 
Shingrix educational program for health care providers would increase their knowledge of the 
vaccine and increase recommendation of the vaccine to their patients.  This scholarly project was 
conducted as an EBP project and utilized the Iowa Model of Evidence-Based Practice.  The 
project design was nonexperimental and was based on previously identified triggers and an 
extensive literature search.  The project used a provider educational intervention with up-to-date 
guidelines to encourage providers to discuss and endorse the Shingrix vaccine to the 
recommended patient population.   
The project coordinator presented an educational program for the providers which 
included information about shingles and the current CDC Guidelines for the Shingrix vaccine.  A 
pretest and posttest consisting of 17 questions each were utilized to determine the provider’s 
knowledge of shingles and the Shingrix vaccine.  The project coordinator planned to audit 
patient charts according to predetermined criteria four weeks prior to the educational program 
and then four weeks after the program to determine if there was an increase in provider 
recommendation for the Shingrix vaccine.  However, on the day of the educational program, the 
project coordinator was alerted by two of the participants that collecting the data from their 
electronic medical record (EMR) was going to pose a problem.  Elaboration on the EMR 
problem will be provided in the Intervention section.  
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Measurable Outcomes 
1. After completion of the educational program and feedback, providers will demonstrate an 
increase in knowledge about the Shingrix vaccine.  This will be evidenced by an increase 
in scores on the provider posttest. 
2. After completion of the educational program, providers will indicate an improvement of 
opinion toward the vaccine and an increase in intent to recommend the Shingrix vaccine 
to their patients, as evidenced by 90% or greater of participants answering “very likely” 
to recommend the Shingrix vaccine.   
3. After completion of the chart audit, providers will demonstrate an increase in 
recommendations for the Shingrix vaccine over a four-week period posteducation, as 
compared to the same time frame prior to the educational program.   
Setting  
 The educational program was conducted at a Central Virginia internal medical practice 
associated with a large hospital system in the area.  The office is located approximately eight 
miles from the city’s downtown area and cares for patients throughout the area.  The office 
comprises 18 providers total including medical doctors, nurse practitioners, and physician’s 
assistants who treat patients 18 years of age and older.  They provide patients medical care by 
utilizing assessment, diagnostic testing, prescription medication, treatment, and referrals. 
 The primary care is affiliated with a large nonprofit hospital and health care system 
located in Central Virginia.  The corporation has a large network of primary care practices, 
family practices, and specialists.  The entire corporation is committed to excellent care.  By 
promoting the new Shingrix vaccine, the project coordinator supported this commitment.   
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The internal medicine office operates with 18 providers including both medical doctors 
and nurse practitioners.  While the office is part of the larger organization, it still functions fairly 
independently.  Key stakeholders primarily include the 18 providers that are employed at this 
location.  One of the physicians helped to direct the project.  The letter of support provided by 
the office manager is included in Appendix C.  The recruitment letter is included in Appendix D.   
Population 
The population of Central Virginia includes different cultures and ethnicities.  The 
internal medicine practice is able to service this area effectively and provide quality patient-
centered care.  The initial population that was evaluated in this scholarly project included the 
providers that are employed by this corporation.  The total number of providers that were invited 
to participate was 18.  The sample that is included is a convenience sample (Moran et al., 2017).   
Inclusion criteria for the patient chart review was anticipated to include patients who 
were over the age of 50 who presented for their annual wellness examination.  In addition, the 
patient needed to be a resident of the Central Virginia region and be a patient at the internal 
medicine practice.  The final inclusion criterion required the patient’s annual wellness 
examination to occur one month prior to the educational program or one month following the 
educational program.   
Ethical Considerations 
The scholarly project coordinator and project chair completed extensive research ethics 
training to ensure protection of human subjects through the Collaborative Institutional Training 
Initiative and were awarded a certificate of successful completion (see Appendix E).  The project 
coordinator continuously reviewed all aspects of this scholarly project to ensure ethical standards 
were maintained throughout the implementation.  The scholarly project was submitted to the 
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Liberty University Institutional Review Board (IRB) for approval.  Approval from the Liberty 
University IRB was obtained, and a copy of the approval form is in Appendix F.  In addition to 
submission to Liberty University’s IRB, the project coordinator submitted to the site’s parent 
organization’s IRB for approval.  The project coordinator received approval from the 
organization’s IRB, and the approval letter is included in Appendix G.   
During the collection of data, the confidentiality of the provider was ensured.  No 
identifying information was obtained from the providers on the pretest or the posttest.  The 
surveys were completed anonymously.  Data obtained within this project will be kept for three 
years and then deleted.   
Data Collection   
Data were obtained from the medical providers on the pretest and posttest during the 
educational intervention at the Central Virginia internal medicine practice.  The data collected 
will be discussed in the results section and be highlighted as they relate to outcomes and 
objectives (Rousch, 2015).  Quantitative comparative data were obtained to investigate the 
differences between the knowledge base of the providers prior to and after the educational 
program (Moran et al., 2017).  An improvement in knowledge after the educational program 
would meet measurable outcome one.  Data were also collected related to the provider’s intent to 
recommend the Shingrix vaccine.  This allowed the project coordinator to evaluate the 
achievement of measurable outcome two. 
Measurable outcome number three was to be met utilizing data from a preintervention 
chart review and a postintervention chart review to compare providers’ recommendation of the 
Shingrix vaccine.  The project coordinator was planning to collect data four weeks prior and four 
weeks following the educational intervention.  Patient data were unable to be collected due to 
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unforeseen circumstances with the practice EMR.  This will be discussed in greater detail in the 
Project Intervention section.  The project coordinator planned to use this data to determine if 
measurable outcome three was achieved.  The implementation of three measurable outcomes 
assisted the project coordinator in determining the change in provider knowledge and 
recommendation.   
Tools 
Demographic survey. A demographic survey was created to determine influencing 
factors related to provider knowledge.  These factors include age, years of practice, and areas of 
practice.  The survey also questioned the participants’ attendance at an in-service about the 
Shingrix vaccine.  The demographic survey is included in Appendix H.   
Pre- and posttest tools. A pretest and posttest were developed by the project coordinator 
based on the CDC guidelines for Shingrix vaccination.  These surveys were created to 
understand the change in providers’ knowledge after the educational session.  Surveying the 
providers allowed the project coordinator to collect reliable data for analysis.  These tests were 
created with the use of Epiform 7 software.  Seveteen multiple-choice knowledge and opinion 
questions surveyed the level of general information about shingles and the Shingrix vaccine held 
by the providers.  The same survey was administered prior to and following the intervention.  
The pretest and posttest are included in Appendix I.  
Retrospective audit tool. The project coordinator developed an audit tool to evaluate the 
impact of the educational program four weeks prior to and four weeks after the intervention.  The 
tool is included in Appendix J.  This tool was not used in the project since the chart analysis did 
not take place.  
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Intervention 
The educational intervention was introduced to the provider group via 30-minute 
PowerPoint presentation.  The educational program was designed to provide information to the 
providers on shingles and the Shingrix vaccine.  Seven providers from the Central Virginia 
internal medicine practice attended and completed the pretest, posttest, and the educational 
intervention.  It was stressed to the providers that the vaccine should result in decreased 
occurrence of the disease.  
In presenting the educational program, the project coordinator discussed all the points 
that were covered by the pretest and posttest.  General knowledge about shingles was included as 
well as a comparison of Zostavax and Shingrix.  Efficacy, contraindications, side effects, and 
dosing were all highlighted in the program.  The providers were educated on their positive 
impact on patient decisions regarding vaccination.  The CDC guidelines for Shingrix were also 
discussed.  Cost and availability of the vaccine were included in the program as well as insurance 
coverage.  At the conclusion of the educational program, time was provided for participant 
questions.  The PowerPoint slides created for the educational program are included in Appendix 
K. 
The internal medicine practice recently updated their EMR system.  This adjustment has 
prevented the providers and nurses from tracking immunizations effectively.  Consultation with 
providers and scribes indicated that they are recommending the Shingrix vaccine to their patients 
but have not found a consistent area to chart this discussion.  Due to the lack of consistency, 
providers stated that they are not recording this information in the EMR.  In addition, patients do 
not require a prescription for the vaccine, so providers are less likely to enter this information.   
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Timeline  
Preparation. During this stage, the project coordinator complied research, finalized the 
proposal, and implemented changes necessary before the implementation phase of the scholarly 
project.   
1. By May 1, 2019, complete primary defense with Dr. Moore 
2. By May 1, 2019, submit proposal to Liberty University’s IRB 
3. By June 1, 2019, submit proposal to site IRB  
Implementation. During this stage the project coordinator presented, the Shingrix 
educational program to the medical staff at the internal medicine practice in Central Virginia.  
Along with the presentation, a pretest and posttest were administered to the providers.  Due to 
unexpected circumstances with the practice’s EMR, the project coordinator was unable to 
complete the chart reviews.  
1. By August 1, 2019, conduct preliminary chart review 
2. By August 1, 2019, complete provider educational program 
3. By August 15, 2019, conduct follow-up chart review 
Evaluation. The EBP was evaluated utilizing the pretest and posttest data fathered during 
the educational intervention.  The data were analyzed and are reported in the results section.  
1. By August 15, 2019, analyze postinterventions  
2. By August 20, 2019, send scholarly project to the editor 
3. By August 31, 2019, conduct the final defense with Dr. Moore 
4. By September 1, 2019, complete final revisions and send to Scholars Crossing 
5. By September 1, 2019, disseminate the information to involved stakeholders 
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Cost-Benefit Analysis 
 A budget for implementation of this scholarly project was not required because there was 
no cost associated.  The project coordinator fulfilled the education intervention and did not 
receive any pro rata payment for her services.   
Data Analysis 
Analysis of descriptive statistics included data from the pretest and posttest.  Data were 
evaluated with the use of SPSS software to analyze measurable outcomes for the project.  Charts 
were created to compare the differences in demographics, answers on the pretest and posttest, 
and intent to prescribe the Shingrix vaccine.  
Measurable outcome 1. The project coordinator reviewed the pretest and posttest results 
after the educational intervention.  The project coordinator utilized SPSS to review and analyze 
the results on both tests and the demographic results.  Through SPSS, the project coordinator 
conducted a t test to assess for any statistically significant differences in knowledge between the 
pretest and posttest.  
Measurable outcome 2. The project coordinator assessed the providers’ intent to 
recommend the Shingrix vaccine via the posttest.  The project coordinator utilized SPSS to 
assess the posttest intent by performing an independent t-test.  The researcher sought to identify 
if the provider education had an influence on provider intent to recommend the Shingrix vaccine.  
Measurable outcome 3. The project coordinator was unable to gather any usable data to 
meet outcome 3 since the information was not available in the practice EMR.  Therefore, this 
measurable outcome was not achieved.  This unexpected barrier was discussed in the 
intervention section and is detailed in the limitations.   
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SECTION FOUR: RESULTS 
Seven provider participants responded to the invitation to attend the educational 
intervention.  The providers were 18 years of age and older and were employed by the identified 
Central Virginia internal medicine practice.  The seven participants (N = 7) completed the 
pretest, observed the educational program, and completed the posttest with a response rate of 
100%.  Six out of seven provider participants completed the demographic survey.  The seven 
provider participants met the inclusion criteria of being a current prescribing provider of the 
internal medicine office and over 18 years of age.   
Descriptive Statistics 
Table 1 details the results of the demographic survey and highlights the frequency of each 
answer.  Additionally, it includes the data that are missing from the demographic survey.  Four 
participants (57%) were male, and three (43%) were female.  The remaining demographic 
information is found in Table 1.   
Table 1  
Participant Demographics 
Variable Frequency %* 
Age   
31–40 1 14.3 
41–50 2 28.6 
51–60 2 28.6 
60 and older 1 14.3 
Years of licensure   
0–3 2 33.3 
8–11 2 33.3 
16 or more 2 33.3 
Primary area of practice   
Primary care 5 83.3 
Family care 1 16.7 
Note. N =6 
*Response totals do not equal 100% due to rounding. 
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Table 2 displays the results of the pretest scores related to knowledge on the topic.  The 
questions that were answered incorrectly most frequently by participants are included.  The 
pretest included 12 knowledge questions and five opinion questions.  On the pretest, there were 
several common misconceptions identified.  The questions most frequently answered incorrectly 
were questions three (What is the average percentage of patients that have postherpetic neuralgia 
after a shingles diagnosis?), six (How effective is Shingrix in preventing the disease?), seven 
(What are the contraindications for the Shingrix vaccine?), nine (Administration is safe for 
individuals who are immunocompromised), and 11 (Medicaid plans cover the Shingrix vaccine). 
Table 2  
Pretest Results 
Question Frequency % 
3   
Correct 4 57.1 
Incorrect 3 42.9 
6   
Correct 5 71.4 
Incorrect 2 28.6 
7   
Correct 2 28.6 
Incorrect 5 71.4 
9   
Correct 2 28.6 
Incorrect 5 71.4 
11   
Correct 4 57.1 
Incorrect  3 42.9 
 
 
Table 3 highlights the number of total correct answers for each provider participant 
within the pretest.  The scores for the knowledge section range from zero to 12, the highest 
possible score.  One individual (14.3%) scored nine or above on the knowledge portion, 
indicating that the individual was educated about the Shingrix vaccine and shingles.  However, 
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85.7% of individuals achieved less than nine questions correctly, indicating that their knowledge 
related to shingles and the Shingrix vaccine could be improved. 
Table 3 
Frequency of Correct Answers on the Pretest 
Number correct Frequency %* 
5 1 14.3 
6 1 14.3 
7 2 28.6 
8 2 28.6 
*Response totals do not equal 100% due to rounding. 
 
Table 4 shows the frequency of answers for knowledge questions included on the 
posttest.  All seven providers correctly answered at least 10 out of 12 of the posttest questions.  
Tables for questions that all seven providers answered correctly are not included.  The question 
answered incorrectly most frequently was question nine, “Administration is safe for individuals 
who are immunocompromised.”  The project coordinator discussed the CDC guidelines related 
to immunization for immunocompromised individuals but also discussed recent studies that have 
shown it is safe for that population within her education program.  This may have caused 
confusion with the providers attending the seminar.  Question three, “What is the average 
percentage of patients that have postherpetic neuralgia after a shingles diagnosis?” was the only 
other question answered incorrectly. 
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Table 4 
Posttest Results 
Question Frequency % 
3   
Correct 6 85.7 
Incorrect 1 14.3 
9   
Correct 4 57.1 
Incorrect 3 42.9 
 
Table 5 highlights the number of total correct answers for each provider participant 
within the posttest.  The highest possible score for questions in the knowledge section was 12.  
All participants scored nine and above on the knowledge portion, indicating that they were 
educated about the Shingrix vaccine and shingles.  No individuals achieved less than nine 
questions correctly on the posttest, which indicates that participant knowledge related to shingles 
and the Shingrix vaccine improved. 
Table 5 
Frequency of Correct Answers on the Posttest 
Correct answers Frequency Percent 
11 4 57.1 
12 3 42.9 
Total 7 100.0 
 
Table 6 showcases the frequency of answers which indicated the providers’ likelihood of 
recommending the vaccine in the pretest.  One question asked participants how confident they 
were in discussing the vaccine with patients utilizing a Likert scale which included very 
confident, confident, slightly confident, and not confident.  Four individuals (57.1%) answered 
that they felt very confident or confident.  Another question using a Likert scale which included 
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very likely, likely, somewhat likely, and not likely as response options in asking providers how 
likely they were to recommend the vaccine.  All individuals answered that they were very likely 
or likely to recommend the vaccine.  The final question asked providers to respond true or false 
to whether they had specific talking points when discussing the Shingrix vaccine. Five (71.4%) 
of participants answered that they had specific talking points about the Shingrix vaccine.   
Table 6 
Pretest Opinion 
Likelihood Frequency % 
Very likely 4 57.1 
Likely 2 28.6 
No response 1 14.3 
 
Table 7 displays the frequency of answers for the providers’ likelihood of recommending 
the vaccine.  The providers answered questions with the Likert scale and answer options 
included very confident, confident, slightly confident, and not confident as well as very likely, 
likely, somewhat likely, and not likely.  The final question asked providers “true or false” if they 
have specific talking points when discussing the Shingrix vaccine.  All individuals answered that 
they felt very confident or confident with vaccine recommendations.  100% of valid answers 
chose that the participant was very likely or likely to recommend the vaccine.  All participants 
answered that they had specific talking points about the Shingrix vaccine. 
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Table 7 
Posttest Opinion 
Likelihood Frequency % 
Very likely 6 71.4 
Likely 1 14.3 
No response 1 14.3 
 
Measurable Outcome 1 
 The first measurable outcome of the project was to determine the difference between the 
provider scores on the pretest and the posttest after the educational intervention.  After 
completion of the educational program and feedback, providers demonstrated an increase in 
knowledge about the Shingrix vaccine.  This was evidenced by an increase in scores on the 
provider posttest.  To identify the impact of the provider educational session, the project 
coordinator compared the frequency of correct answers in the pretest and posttest.   
The project coordinator utilized the independent samples t test to compare the providers’ 
knowledge before and after the educational intervention.  The pretest and posttest means, 
standard deviations, and standard error means were recognized.  Tables 8 and 9 highlight the 
comparison of the obtained data.   
Table 8 
 
Mean, Standard Deviation, and Standard Error of Provider Knowledge Scores 
Test Correct M SD SEM 
Pretest 7 7.2857 1.60357 .60609 
Posttest 7 11.4286 0.53452 .20203 
Note. p < .0005.  
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Table 9 
Independent T-test for Provider Knowledge 
 
 Levene’s test   t test for equality of means 
         95% CI 
 F Sig. 
 
t df 
Sig. 
(2-tailed) 
M 
difference 
SE 
difference Lower Upper 
Equal 
variances 
assumed 
3.575 .083  -6.485 12 .000 -4.14286 .63888 -5.53485 -2.75086 
Equal 
variances 
not 
assumed 
   -6.485 7.317 .000 -4.14286 .63888 -5.64039 -2.64532 
 
 
Measurable Outcome 2   
Determining the impact of the provider educational session, the project coordinator 
compared the providers’ opinion of and intent to recommend the vaccination prior to and 
following the educational intervention.  Achievement of this measurable outcome was 
determined by the accomplishment of 90% of providers stating that they would be “very likely” 
to recommend the vaccine.  The 90% target outcome was not achieved because only 83.3% of 
valid answers were indicated as “very likely.” While this measurable outcome was not met, there 
was an increase in those who indicated that they were “very likely” to recommend the vaccine.  
These results indicate possible clinical significance.  Six providers answered that they would be 
“very likely” to recommend the vaccine, one provider indicated “likely” to recommend the 
vaccine, and one provider did not respond.   
 
Measurable Outcome 3  
The project coordinator had planned to conduct a chart audit to demonstrate an increase 
in recommendations of the Shingrix vaccine over a four-week period posteducation as compared 
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to the same time frame prior to the educational program.  Providers were expected to 
demonstrate an increase in recommendations for the Shingrix vaccine over a two-week period 
posteducation as compared to the same time frame prior to the educational program.  Patient 
criteria for the chart review was to include individuals who were enrolled as patients at the 
internal medicine practice, were 50 years of age or older, and were presenting for an annual 
wellness exam during the defined time frame.  
The chart review was cancelled when the project coordinator learned there was 
insufficient EMR data related to Shingrix vaccination to allow for an effective analysis of this 
outcome.  Therefore, measurable outcome 3 was not met due to this unexpected factor.   
SECTION FIVE: DISCUSSION 
The scholarly project was created to identify the impact of a provider education program 
and assess provider knowledge about the Shingrix vaccine.  The project coordinator had a 
positive impact on provider recommendation of the immunization as evidenced by the posttest 
results.  Demographic factors were also considered due to their influence on provider knowledge 
and opinion.  The results indicate statistical significance for an increase in provider knowledge 
and reconfirmed the need for this evidence-based education intervention.  The literature review 
revealed extensive findings related to the Shingrix vaccine and existing vaccine educational 
interventions.  The strengths, limitations, and implications for practice related to this scholarly 
project are discussed to provide future direction for research and practice.   
Strengths 
 The pretest and posttest surveys were a cost-effective method used within this scholarly 
project.  The methodology provided for ease of pretest and posttest data collection.  The project 
coordinator completed the educational intervention with no financial assistance from the health 
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care organization where the EBP project was conducted or an outside organization.  Costs were 
minimal and included printing and paper for the surveys.  Data that were collected from the 
pretest and posttest efficiently.  The project coordinator was able to compile and analyze the data 
effectively to determine significance.  Based on the results, two of the project’s three measurable 
outcomes were met.  Education on the new Shingrix vaccine increased the postintervention 
knowledge of all the providers that participated in the educational program.  Posteducation, all 
providers either stated they were “very likely” or “likely” to recommend the Shingrix vaccine to 
their patients.   
Limitations 
The most significant limitation related to this scholarly project was the lack of pre- and 
post-intervention patient data from the EMR.  The project coordinator was unable to complete 
the chart review as previously planned; therefore, the project lacked the evaluation data to 
compare preintervention to postintervention provider recommendations of the Shingrix vaccine.  
The health care organization recently switched to a new EMR.  This adjustment has prevented 
the providers and nurses from tracking immunizations effectively.   
Health information from the previous charting system was scanned into the patients’ new 
records, but the system is not capturing the information on the scanned document.  The provider 
or nurse needs to enter each immunization manually for each patient to accurately track his or 
her vaccine status.  In addition, the Shingrix vaccine currently has limited availability, so 
providers are writing paper prescriptions for their patients rather than e-prescribing the vaccine.  
The Shingrix vaccine is currently available at pharmacies without a prescription, so many 
providers are discussing the immunization with their patient but are not noting this discussion in 
the EMR.   
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Project data show the significance of the educational program in affecting the provider’s 
increased knowledge of and increased intent to recommend the Shingrix vaccine.  However, 
another limitation of the project was the small sample size of providers who participated in the 
educational program.  Providers were selected through convenience sampling and were invited, 
but not required, to attend the presentation.   
Implications for Practice and Research 
 The Shingrix vaccine has been indicated by research as more than 90% effective for 
prevention against the herpes zoster virus, but due to its recent release, many providers have not 
been educated on the vaccine and are wary to recommend it to their patients (CDC, 2018).  This 
scholarly project demonstrates the effectiveness of further education for providers about the 
Shingrix immunization.  Targeted interventions for immunization education lead to an increase 
in provider knowledge, a change of provider opinion toward the vaccination, and an increase in 
provider recommendation of the vaccination (Ridda et al., 2009).   
Patients have indicated that their most trusted resource for health care information is their 
primary care provider.  If the patient’s primary care provider recommends the vaccine, the 
patient is more likely to pursue the immunization.  Shingles is a financial burden to the United 
States health care system, and by the implementation of targeted vaccine education for providers, 
the burden can be lessened.  In-services about shingles for providers should be more accessible.  
In addition, further research should be completed on educational programs that are specific to the 
Shingrix vaccine as well as other new vaccines or medications.  The project coordinator did not 
identify any studies that include education for providers about the Shingrix immunization.   
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Sustainability 
Outcomes and data obtained from the scholarly project will be monitored in the original 
location (Hall & Roussel, 2014).  The educational program has been shared with the office 
manager.  The manager was informed that she can distribute the PowerPoint to the staff as a 
reference.  In addition, the PowerPoint presentation was shared with the lead physician in hopes 
that he will share it when he trains new providers at his practice location.  Appropriateness of the 
scholarly project will be considered before integrating the project on a greater scale within the 
defined setting (Hall & Roussel, 2014).  The project has been successfully completed in one 
internal medicine office location, and this project coordinator is hoping to implement the 
education program in her area of future practice.   
Dissemination Plan 
The project coordinator is planning on partnering with the office manager at the internal 
medicine practice and one of the physicians to inform health care providers of the findings of the 
scholarly project.  In addition, the medical director will be notified of the results.  A document 
has been compiled to send to the office manager including the results tables and will be sent via 
email to distribute to the staff.  The target audience of the email will primarily include 
physicians, nurse practitioners, nurses, and physician assistants.  The scholarly project will be 
submitted to Liberty University’s Scholars Crossing to reach a larger audience, and the project 
manager’s manuscript will be submitted to the Vaccine journal.   
CONCLUSION 
 This scholarly project validates the need for further research and indicates the positive 
impact of a focused educational intervention for providers.  Due to the continuous influx of 
information in health care, providers need to prioritize continuing education.  Education on the 
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Shingrix vaccine was highlighted due to its recent release as well as its efficacy.  Currently, 
prescribing providers and patients are limited by the availability of the vaccine.  There is a 
supply and demand imbalance, but the manufacturing company is continuing to respond to the 
needs of the patient population.  As the vaccine becomes more readily available, providers 
should be prepared to discuss the immunization, side effects, cost, and insurance coverage.  
Following education about the Shingrix vaccine, prescribing providers indicated that they were 
more likely to recommend the immunization.  Improved education increases a prescribing 
provider’s confidence and discussion points with patients.   
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Levels of Evidence  
 
Article Title, 
Author, etc. 
(Current APA 
Format) 
Study 
Purpose Sample  Methods 
Study 
Results 
Level of 
Evidence 
Study 
Limitations 
Would Use as 
Evidence to 
Support a 
Change? (Yes 
or No) Provide 
Rationale. 
Bharucha, T., Ming, 
D., & Breuer, J. 
(2017). A critical 
appraisal of 
“Shingrix”, a novel 
herpes zoster subunit 
vaccine (HZ/Su or 
GSK1437173A) for 
varicella zoster 
virus. Human 
Vaccines & 
Immunotherapeutic, 1
3(8), 1789–1797. 
doi:10.1080/21645515
.2017.1317410 
Shingrix is the 
first time a 
subunit 
vaccine is 
available and 
has been 
indicated as 
effective.   
Three studies 
that focus on 
the general 
population, 
elderly, and 
HIV infected 
individuals 
A systematic 
review of 
three different 
studies 
The vaccine 
indicated 
strong 
efficacy in all 
populations 
Level 1: 
Systematic 
review 
Study did not 
investigate 
all potential 
aspects of the 
population.   
Yes. Supports the 
claim to providers 
that the 
immunization 
should be 
considered with 
eligible 
candidates.  
Bowser, A. D. (2017). 
In close vote, advisory 
panel prefers Shingrix 
over Zostavax. 
Internal Medicine 
News, 50(19). 
Retrieved from 
Experts were 
asked to vote 
to determine if 
the Shingrix 
vaccine should 
be 
Fifteen 
experts were 
included.  
An expert 
opinion 
Experts voted 
that the 
Shingrix 
vaccine  
Level 6: 
Descriptive 
study 
An expert 
panel does 
not reflect as 
high of a 
level of 
evidence.   
Yes. It supports 
the idea that 
providers should 
be recommending 
the Shingrix 
vaccine.   
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https://www.mdedge.c
om/internalmedicine 
recommended 
to patients.   
Busby, C. (2018). Not 
just for kids: How to 
improve adult 
vaccination uptake in 
Canada (Commentary 
No. 509). Retrieved 
from C. D. Howe 
Institute website: 
https://www.cdhowe.o
rg/sites/default/files/att
achments/research_pa
pers/mixed/Commenta
ry_509.pdf 
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reasons behind 
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rates of adult 
vaccination in 
Canada 
Residents of 
British 
Columbia 
Surveys were 
distributed 
according to 
immunization 
status and 
reasons for 
their status.   
Patients who 
were 
vaccinated 
stated that 
their health 
care provider 
recommende
d it to them.  
People that 
indicated 
they were not 
vaccinated 
felt as though 
they did not 
have access 
to the 
vaccine.   
Level 4: 
Correlational 
Design 
Study was 
completed in 
Canada, and 
demographic
s and 
population 
could have 
an impact on 
patient’s 
actions and 
attitudes.   
Yes. Indicates that 
education related 
to the vaccine 
from the provider 
has an impact on 
the patient’s 
actions.   
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Clark, R. C., Jackson, 
J., Hodges, D., 
Gilliam, B., & Lane, J. 
(2015). Improving 
pneumococcal 
immunization rates in 
an ambulatory 
setting. Journal of 
Nursing Care 
Quality, 30(3), 205-
211. 
doi:10.1097/ncq.0000
000000000110 
Understand 
the impact that 
vaccination 
education can 
have on a 
specific 
population 
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risk for 
pneumonia 
who were 
treated in a 
pre-surgical 
center 
Quasi-
experimental 
design which 
evaluated the 
results of 
educational 
flyers.   
Targeted 
education 
with flyers 
led to 
increased 
vaccination 
levels.   
Level 3: 
Quasi- 
Experimental 
Design 
Investigates 
education 
catered to 
pneumococc
al education 
rather than 
Shingles.   
Yes. If patients are 
given the 
appropriate 
education 
materials by the 
health care 
provider, they are 
more likely to be 
vaccinated.   
Dubé, E., Gagnon, D., 
Ouakki, M., Bettinger, 
J. A., Guay, M., 
Halperin, S., . . . 
Canadian 
Immunization, R. N. 
(2016). Understanding 
vaccine hesitancy in 
Canada: Results of a 
“To identify 
the views of 
Canadian 
vaccination 
experts and 
health 
professionals 
concerning the 
definition, 
52 research 
networks 
members and 
98 health 
care 
providers 
completed 
the first 
survey, and 
Two separate 
surveys were 
administered 
to randomized 
groups   
All parties 
were 
concerned 
regarding the 
decline of 
vaccination 
rates overall 
in Canada, 
but many 
Level 2: 
Randomized 
controlled 
trial 
Study was 
located in 
Canada and 
also 
considered 
opinions 
from 
research 
Yes, supports that 
providers feel 
improperly 
educated to speak 
with vaccine 
hesitant 
individuals and 
that they require 
further education.   
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consultation study by 
the Canadian 
immunization research 
network. PLoS 
One, 11(6). 
doi:10.1371/journal.po
ne.0156118 
scope, causes, 
and 
consequences 
of vaccine 
hesitancy in 
Canada” 
(Dubé et al., 
2016, p. 1).   
 
53 research 
networks 
members and 
80 health 
care 
providers 
providers 
stated that 
they felt 
improperly 
counseled to 
advise 
vaccine 
hesitant 
patients. 
networks 
members.   
Elliott, J. C. (2018). 
Zoster vaccine 
recombinant 
adjuvanted 
(Shingrix). Infectious 
Disease Alert, 37(4).  
Retrieved from 
https://www.reliasmed
ia.com/newsletters/18/
issues/76568 
Determine 
effectiveness 
of Shingrix 
vaccine in 
different age 
groups.  
Study groups 
were 
separated 
into 
individuals 
older than 50 
years and 
individuals 
older than 70 
years   
A randomized 
controlled trial  
The vaccine 
was found to 
be effective 
in all 
populations.   
Level 2: 
Randomized 
controlled 
trial 
The study 
excluded 
those who 
were 
immunocom
promised or 
had 
previously 
been 
diagnosed 
with 
Shingles   
Yes. This study 
indicates that the 
vaccine is 
effective in those 
over 50 years of 
age and should be 
recommended.   
Friesen, K. J., 
Chateau, D., Falk, J., 
Alessi-Severini, S., & 
Bugden, S. (2017). 
Cost of shingles: 
Population based 
To identify the 
health care 
system burden 
caused by 
shingles 
Costs related 
to shingles 
April 1, 1997 
to March 31, 
2014 were 
considered 
This data was 
collected with 
the 
implementatio
n of 
administrative 
The recent 
increase in 
shingles 
diagnoses has 
increased the 
financial 
Level 5: Case 
control 
studies 
Study was 
only 
conducted in 
the province 
of Manitoba 
Yes, indicates that 
the cost related to 
shingles is a great 
burden on the 
health care 
system, and an 
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burden of disease 
analysis of herpes 
zoster and postherpetic 
neuralgia. BMC 
Infectious 
Diseases, 17. 
doi:10.1186/s12879-
017-2185-3 
 
for Manitoba, 
Canada  
 
healthcare 
data from the 
province of 
Manitoba, 
Canada 
burden 
related to 
shingles.   
intervention to 
decrease these 
costs would be 
beneficial  
 GSK phase III study 
supports safety & 
efficacy of Shingrix in 
preventing shingles in 
auHSCT patients 
[Clinical report]. 
(2017). PharmaBiz. 
Retrieved from 
http://www.pharmabiz
.com/ 
Determine 
Shingrix’s 
efficacy in 
patients who 
have 
undergone a 
stem cell 
transplant 
1846 subjects 
from 28 
different 
countries 
A randomized 
controlled trial 
that 
determined 
efficacy.  
Indicated 
almost 70% 
efficacy in 
patients with 
a stem cell 
transplant 
Level 2: 
Randomized 
controlled 
trial 
Only focused 
on patients 
with stem 
cell 
transplant  
Yes, indicates that 
providers can 
recommend this 
vaccine to this 
specific 
population 
Jacobson, R. M., St. 
Sauver, J. L., & 
Rutten, L. J. F. (2015). 
Vaccine hesitancy. 
Mayo Clinic 
Proceedings, 90(11), 
1562–1568. 
To discuss the 
best response 
to vaccine 
hesitancy from 
parents and 
patients 
Available 
data 
regarding 
vaccine 
hesitancy  
Examined 
existing 
systematic 
reviews 
related to the 
topic 
Usage of 
point of care 
reminders, 
reminder 
recall 
communicati
ons and 
standing 
Level 6: 
Descriptive 
study 
Low level of 
evidence 
does not as 
strongly 
support a 
change in 
practice.   
Yes, supports the 
need for further 
provider 
intervention 
related to 
vaccination. 
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doi:10.1016/j.mayocp.
2015.09.006.  
orders 
implemented 
by the 
physician 
would help 
improve  
Jones, A. M., Omer, S. 
B., Bednarczyk, R. A., 
Halsey, N. A., 
Moulton, L. H., & 
Salmon, D. A. (2012). 
Parents’ source of 
vaccine information 
and impact on vaccine 
attitudes, beliefs, and 
nonmedical 
exemptions. Advances 
in Preventive 
Medicine, 1(8). 
doi:10.1155/2012/932
741 
To identify 
factors that 
influenced 
parents 
vaccinating 
their children 
1367 parents  1,000 schools 
across 
Colorado, 
Massachusetts
, Missouri, 
and 
Washington 
separated by 
vaccine uptake  
 
The most 
common 
resource of 
vaccine 
related 
information 
is obtained 
from the 
patient’s 
provider 
Level 3: 
Quasi-
Experimental  
Limited to 
the 
population 
located in 
specific 
states 
Yes, supports the 
notion that most 
parents are 
obtaining 
information from 
providers.  
Therefore, 
providers need 
additional support 
and guidance.   
Kaplan-Weisman, L., 
Waltermaurer, E., & 
Crump, C. J. (2018). 
Assessing  
and improving zoster 
vaccine uptake in a 
To determine 
if targeted 
interventions 
could increase 
shingles 
103 patients 
based from a 
local 
homeless 
shelter 
A cohort study 
that targeted 
homeless 
patients 
located in a 
nearby shelter 
Targeted 
education by 
a physician 
as well as 
providing the 
opportunity 
Level 3: 
Quasi- 
experimental 
Study 
It was 
limited to a 
smaller 
sample that 
was 
concentrated 
Yes. Indicates that 
provider 
understanding and 
targeted education 
for patients 
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homeless population. 
Journal of Community 
Health. 
doi:10.1007/s10900-
018-0517-x 
vaccination 
rates 
increased 
vaccination 
rates 
in a specific 
area.   
increases 
vaccination rates.   
Kawai, K., 
Gebremeskel, B. G., & 
Acosta, C. J. (2014). 
Systematic review of 
incidence and 
complications of 
herpes zoster: 
Towards a global 
perspective. BMJ 
Open, 4(6). 
doi:10.1136/bmjopen-
2014-004833 
 
       
Krieger, J. W., 
Castorina, J. S., Walls, 
M. L., Weaver, M. R., 
& Ciske, S. (2000).  
Increasing influenza 
and pneumococcal 
immunization rates: A 
randomized controlled 
study of a senior 
Determine the 
impact that 
additional 
education can 
have on 
vaccination 
rates.   
Randomized 
participants 
65 years and 
older who 
were 
participants 
in a local 
senior center.   
A randomized 
controlled trial 
that provided 
selected 
participants 
with 
additional 
educational 
materials.   
Immunizatio
n rates 
increased as a 
result of 
pamphlets 
and other 
educational 
materials that 
were 
Level 2: 
Randomized 
Controlled 
Trial 
This is a 
smaller study 
that was 
concentrated 
at one 
location.  
This study 
focuses on 
Yes. This 
indicates that 
distributed 
materials that are 
provided to 
patients from a 
trusted location 
have an impact on 
decision making 
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center–based 
intervention. American 
Journal of Preventive 
Medicine, 18(2), 123-
131. 
doi:10.1016/s0749-
3797(99)00134-8 
distributed to 
patients.   
education for 
pneumonia.   
related to 
vaccines.  
Providers should 
provide these 
materials to their 
patients.   
Leask, J., Kinnersley, 
P., Jackson, C., 
Cheater, F., Bedford, 
H., & Rowles, G. 
(2012). 
Communicating with 
parents about 
vaccination: A 
framework for health 
professionals. BMC 
Pediatrics, 12(1). 
doi:10.1186/1471-
2431-12-154 
To identify 
different 
parental 
attitudes about 
vaccination 
and to identify 
which ways 
providers felt 
would be best 
to educate 
them 
112 articles 
related to this 
topic were 
reviewed and 
then 104 
immunization 
providers 
were 
surveyed 
A systematic 
review related 
to the topic 
was initially 
completed, 
and then 
surveys were 
administered  
Five specific 
parental 
opinions 
regarding 
vaccination 
were 
identified and 
then 
providers 
identified 
more 
frequently 
that a guiding 
style was 
helpful  
Level 3: 
Quasi-
Experimental 
The sample 
was not 
randomized.  
Yes, while most 
providers 
indicated that a 
guiding style 
discussion with 
the patient was 
most helpful, there 
were still areas for 
improvement 
identified in 
provider 
knowledge.   
Loehr, J., & Savoy, M. 
(2016). Strategies for 
Addressing and 
Overcoming Vaccine 
Hesitancy. American 
To discuss 
methods to 
encourage 
vaccine 
hesitant 
None 
identified 
Research 
relating to 
how to 
address 
concerns of 
Strong 
favorable 
recommendat
ions 
regarding 
Level 6: 
Descriptive 
study 
Low level of 
evidence  
Yes, indicates that 
further education 
for providers is 
necessary.  
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Family Physician, 
94(2), 94–96. 
Retrieved from 
https://www.aafp.org/j
ournals/afp.html 
patients and 
families 
vaccine 
hesitant 
parents was 
identified 
vaccination 
can help 
influence 
decisions 
MacDougall, D. M., 
Halperin, B. A., 
MacKinnon-Cameron, 
D., Li, L., McNeil, S. 
A., Langley, J. M., & 
Halperin, S. A. (2015). 
The challenge of 
vaccinating adults: 
Attitudes and beliefs 
of the Canadian public 
and healthcare 
providers. BMJ Open, 
5(9). 
doi:10.1136/bmjopen-
2015-009062 
Assess 
knowledge of 
patients and 
providers 
related to 
vaccine 
preventable 
diseases 
4023 patients 
were 
surveyed and 
62 were 
involved in 
focus groups 
and 1167 
providers 
were 
surveyed and 
45 were in 
the focus 
groups 
Both surveys 
and focus 
groups were 
utilized to 
determine 
knowledge of 
providers and 
the public  
Knowledge 
related to 
vaccination 
was lacking 
in both study 
groups 
Level 3: 
Quasi-
experimental 
This is a 
convenience 
sample.  
Data was 
obtained 
from 
providers 
and patients 
that reside in 
Canada.   
Yes, it supports 
the need for 
further evidence 
for providers 
overall.  
Oakes, K. (2017). 
New shingles vaccine 
earns FDA panel nod: 
Shingrix shows 91.3% 
efficacy in seniors. 
Internal Medicine 
News, 50(16), 1+. 
To determine 
the efficacy of 
the Shingrix 
vaccine.   
29,000 
subjects 
globally 
A randomized 
controlled trial 
determining 
effectiveness 
The vaccine 
was more 
than 90% 
effective in 
all 
populations.   
Level 2: 
Randomized 
controlled 
trial 
There was a 
smaller 
group of 
subjects that 
were 
concentrated 
Yes. This article 
supports the 
efficacy of the 
vaccine, and 
therefore indicates 
that providers 
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Retrieved from 
https://www.mdedge.c
om/internalmedicine 
in the United 
States.   
should offer it to 
their patients.   
Paterson, P., Meurice, 
F., Stanberry, L. R., 
Glismann, S., 
Rosenthal, S. L., & 
Larson, H. J. (2016). 
Vaccine hesitancy and 
healthcare providers. 
Vaccine, 34(52), 6700-
6706. 
doi:10.1016/j.vaccine.
2016.10.042 
To evaluate 
the influence 
of the health 
care 
provider’s 
opinion on 
vaccination 
rates  
310 articles 
were 
included  
An evaluation 
of existing 
research relate 
to the topic 
was 
considered   
Many factors 
including 
preparedness,  
Level 1: 
Systematic 
review 
Considers 
many 
different 
factors rather 
than just 
knowledge 
related to 
vaccines 
Yes, supports the 
need to educate 
providers to 
increase vaccine 
uptake.   
Perkins, R. B., 
Zisblatt, L., Legler, 
A., Trucks, E., 
Hanchate, A., & 
Gorin, S. S. (2015). 
Effectiveness of a 
provider-focused 
intervention to 
improve HPV 
vaccination rates in 
boys and 
girls. Vaccine, 33(9), 
1223-1229. 
To identify if 
an educational 
program with 
providers 
increased 
overall 
vaccination 
rates for the 
HPV vaccine 
in pediatric 
patients.  
3961 girls 
and 6910 
boys from 
two 
community 
health centers 
in an inner 
city 
neighborhood  
Educational 
sessions were 
conducted 
with the 
providers who 
volunteered 
from the 
selected 
offices, and 
vaccination 
rates were 
compared for 
patients in the 
Girls who 
were patients 
at the 
intervention 
practice were 
more likely 
to be 
vaccinated 
when 
compared 
with the 
control 
group.  
Level 3: 
Quasi-
Experimental 
study 
Study was 
not 
randomized 
and was only 
focused in 
one inner 
city 
neighborhoo
d.   
Yes, this indicates 
that more provider 
education has a 
positive impact on 
immunization.  
Patients of 
providers who are 
educated were 
more likely to be 
vaccinated.   
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doi:10.1016/j.vaccine.
2014.11.021 
control group 
against those 
whose 
providers 
received 
education.  
Vaccination 
rates for boys 
stayed about 
the same 
when 
compared 
with control.   
Prioli, K., Formal, R., 
Schafer, J., Harris, L. 
F., Jackson, F., 
Vertsman, R., & Pizzi, 
L. (2018). Baseline 
knowledge about 
vaccines and vaccine-
preventable diseases 
among older adults: 
Preliminary baseline 
analysis of the vaccine 
education through 
pharmacists and senior 
centers (VEPSC) 
study. Value in 
Health, 21. 
doi:10.1016/j.jval.201
8.04.1031 
To determine 
the knowledge 
base of older 
adults related 
to vaccines.   
45 older 
adults present 
in a senior 
care setting 
Cohort study 
that surveyed 
a group of 
elderly 
citizens living 
in a senior 
care facility. 
Determined 
that 
knowledge 
related to 
vaccines in 
general was 
minimal. 
Level 3: 
Quasi-
experimental 
study 
Study was 
limited to a 
small study 
group 
located in 
one area 
Yes. Education 
can be improved 
in many different 
settings for 
patients by better 
education.  
Providers can take 
on a larger role to 
ensure that their 
patients are 
informed.   
Real, F. J., DeBlasio, 
D., Beck, A. F., 
To identify the 
impact of a 
45 residents 
who are 
Chosen 
interventional 
There was a 
decreased 
Level 3; 
Quasi-
Study was 
not 
Yes, it indicates 
that improved 
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Ollberding, N. J., 
Davis, D., Cruse, 
B., … Klein, M. D. 
(2017). A virtual 
reality curriculum for 
pediatric residents 
decreases rates of 
influenza vaccine 
refusal. Academic 
Pediatrics, 17(4), 
431–435. 
doi:10.1016/j.acap.201
7.01.010 
virtual reality 
educational 
program 
related to 
vaccine 
working at 
Cincinnati 
Children’s 
Hospital 
Medical 
Center 
(CCHMC) 
pediatric 
primary care 
center 
(PPCC). 
group that 
received 
virtual reality 
training was 
compared to 
control group 
rate of 
vaccine 
refusal for 
the patients 
of the 
residents that 
were enrolled 
in the 
educational 
program 
experimental 
study 
randomized 
and 
controlled.  
provider 
educational 
increases their 
personal 
knowledge and 
leads to increased 
vaccination rates.   
Reiter, P. L., Stubbs, 
B., Panozzo, C. A., 
Whitesell, D., & 
Brewer, N. T. (2011). 
HPV and HPV 
Vaccine education 
intervention: Effects 
on parents, healthcare 
staff, and school 
staff. Cancer 
Epidemiology, 
Biomarkers & 
Prevention, 20(11). 
To determine 
the impact that 
education 
related to 
vaccination 
could have on 
the 
population.  
Sample 
included 
parents, 
school staff, 
and health 
care staff 
A cohort study 
that focuses 
on three 
different 
groups and 
their 
education.   
Indicated that 
knowledge 
was 
improved 
following 
targeted 
education.   
Level 3: 
Quasi-
experimental 
study 
Study was 
limited to 
those 
subjects 
available.  
Examines 
education 
related to 
HPV rather 
than 
Shingles.  
Yes. Indicates that 
education related 
to immunization is 
important for the 
community to 
ensure educated 
decision making 
from patients and 
parents.   
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doi:10.1158/1055-
9965 
Ridda, I., Macintyre, 
C., & Lindley, R. 
(2009). A qualitative 
study to assess the 
perceived benefits and 
barriers to the 
pneumococcal vaccine 
in hospitalized older 
people. Vaccine, 27(28
), 3775-3779. 
doi:10.1016/j.vaccine.
2009.03.075 
Identify 
attitudes 
towards 
vaccination, 
and determine 
why many 
individuals 
were not 
immunized 
Elderly 
patients who 
were 
admitted to 
an 800-bed 
hospital 
Open ended 
interviews 
were 
conducted to 
determine why 
patients 
received or 
refused 
vaccination.   
Patients 
stated that 
one of the 
reasons that 
they did not 
consider the 
vaccination 
was because 
their provider 
did not 
recommend 
it.  In 
addition, 
patients were 
afraid to 
develop 
illness.   
Level 6: 
Descriptive 
study 
This is a 
lower level 
of evidence 
and obtained 
data from 
open ended 
interviews.   
Yes. This is a 
lower level of 
evidence, 
however, indicates 
that providers are 
not consistently 
recommending 
immunizations to 
their patients 
according to 
guidelines.   
Sadaf, A., Richards, J. 
L., Glanz, J., Salmon, 
D. A., & Omer, S. B. 
(2013). A systematic 
review of 
interventions for 
reducing parental 
vaccine refusal and 
Identify 
methods to 
address 
parental 
refusal of 
vaccines 
25 different 
studies 
relating to 
this topic 
Systematic 
review of data 
obtained 
Evidence was 
not as 
convincing to 
support a 
specific 
intervention, 
but most 
studies 
Level 1: 
Systematic 
review 
Most of the 
studies 
evaluated by 
the 
systematic 
review were 
descriptive 
studies, and 
Yes. Reminders 
for physicians and 
provider based 
education 
programs were 
among the 
interventions that 
were evaluated, 
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vaccine hesitancy. 
Vaccine, 31(40), 4293-
4304. 
doi:10.1016/j.vaccine.
2013.07.013 
indicated that 
an 
intervention 
improved 
parents’ 
intention to 
vaccinate 
their children 
therefore 
lower level 
of evidence 
and this supports 
that change.   
Schnaith, A. M., 
Evans, E. M., Vogt, 
C., Tinsay, A. M., 
Schmidt, T. E., 
Tessier, K. M., & 
Erickson, B. K. 
(2018). An innovative 
medical school 
curriculum to address 
human papillomavirus 
vaccine hesitancy. 
Vaccine, 36(26), 3830-
3835. 
doi:10.1016/j.vaccine.
2018.05.014 
To determine 
if an 
educational 
program 
catered to 
medical 
students 
would 
increase the 
likelihood of 
them advising 
their patients 
to be 
vaccinated for 
HPV 
101 medical 
students 
enrolled at 
the 
University of 
Minnesota 
Pre-survey 
and post-
survey were 
administered 
accordingly 
Medical 
students 
indicated that 
following the 
educational 
program that 
they were 
more likely 
to 
recommend 
the HPV 
vaccine 
Level 3: 
Quasi-
experimental 
study 
Study was 
limited to 
one group of 
students, and 
sample was 
not 
randomized 
Yes, indicates that 
provider education 
increases 
likelihood of the 
provider to 
recommend the 
vaccination.   
Suryadevara, M., 
Bonville, C. A., 
Cibula, D. A., & 
Domachowske, J. B. 
To determine 
if provider, 
health care 
staff, patient 
46 providers 
from 6 
pediatric 
offices in 
A 2-phase 
program was 
implemented 
where 
Vaccination 
rates for HPV 
increased by 
at least 10% 
Level 3: 
Quasi-
Experimental 
Study only 
includes six 
pediatric 
offices.  
Yes, indicates that 
increased provider 
education about 
the benefits of 
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(2019). Cancer 
prevention education 
for providers, staff, 
parents, and teens 
improves adolescent 
human papillomavirus 
immunization rates. 
The Journal of 
Pediatrics, 205. 
doi:10.1016/j.jpeds.20
18.09.013 
and parent 
education 
about the 
vaccine and 
cancer 
prevention 
improved 
compliance 
with the HPV 
vaccination 
upstate New 
York and 
their patients  
providers and 
staff are 
educated, and 
a patient and 
parent 
education 
program is 
conducted.   
in three 
practices and 
increased by 
at least 5% in 
five 
practices.   
Study is only 
located in a 
suburban 
area in New 
York.   
vaccination 
improves overall 
vaccination rates.   
Toyama, N., & 
Shiraki, K. (2018). 
Universal varicella 
vaccination increased 
the incidence of 
herpes zoster in the 
child-rearing 
generation as its short-
term effect. Journal of 
Dermatological 
Science. 
doi:10.1016/j.jdermsci
.2018.07.003 
Determine the 
impact that 
varicella 
vaccination 
has on herpes 
zoster in 
Japan. 
Patients 
randomized 
from 43 
clinics in 
Japan  
Randomized 
controlled 
selection of 
subjects  
Indicated that 
shingles has 
increased 
related to the 
varicella 
vaccine.   
Level 2: 
Randomized 
controlled 
trial 
Study is 
located only 
in Japan 
This indicates that 
shingles has 
increased related 
to varicella 
vaccination and it 
is important that 
both providers and 
patients are aware.   
Zacks Equity 
Research. (2018, 
January 28). Glaxo's 
To determine 
if the Shingrix 
Experts 
affiliated 
with the 
Expert opinion 
discussed the 
efficacy and 
Experts 
determined 
that they 
Level 6: 
Descriptive 
study 
An expert 
opinion is 
not as 
Indicates that the 
EU also supports 
marketing and 
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shingles vaccine 
Shingrix gets positive 
CHMP opinion. 
Retrieved from 
https://www.zacks.co
m/    
vaccine is safe 
to market  
European 
Union 
marketability 
of the 
Shingrix 
vaccine 
would 
recommend 
the vaccine 
according to 
the research 
found.   
indicative of 
a practice 
change as a 
trial or 
systematic 
review.   
recommendations 
from the providers 
for patients to be 
vaccinated.   
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Appendix B 
You have permission, as requested today, to review and/or reproduce The Iowa Model of Evidence-Based Practice to Promote 
Quality Care (Revised 1998).  Click the link below to open.  
 
The Iowa Model of Evidence-Based Practice to Promote Quality Care (Revised 1998)  
 
Copyright is retained by University of Iowa Hospitals and Clinics. Permission is not granted for placing on the internet.  
 
Citation: Titler, M. G., Kleiber, C., Steelman, V. J., Rakel, B.A., Budreau, G., Everett, L. Q., ...Goode, C. J. (2001). The Iowa 
model of evidence-based practice to promote quality care. Critical Care Nursing Clinics of North America, 13(4), 497-509.  
   
In written material, please add the following statement:  
Used/reprinted with permission from the University of Iowa Hospitals and Clinics, copyright 1998. For permission to use or 
reproduce, please contact the University of Iowa Hospitals and Clinics at 319-384-9098 . 
   
Please contact UIHCNursingResearchandEBP@uiowa.edu or 319-384-9098 with questions.  
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Appendix D  
Recruitment Letter 
 
3/29/2019 
 
Provider of VHC Falls Church  
400 S. Maple Avenue, Suite 200 
Falls Church, VA 22046 
 
Dear Provider of VHC Falls Church: 
 
As a graduate student in the Doctoral of Nursing Practice Program at Liberty University, I am 
conducting research as part of the requirements for a doctoral degree. The purpose of my 
research is to identify if a Shingrix education program for providers leads to increased overall 
knowledge for practitioners, and increased recommendations for patient vaccination, and I am 
writing to invite you to participate in my study.  
 
If you are 18 years of age or older, and are willing to participate, you will be asked to take a pre-
test, observe an educational program, and take a posttest.  It should take approximately thirty 
minutes for you to complete the procedures listed. Your participation will be completely 
anonymous, and no personal, identifying information will be collected. 
  
To participate, please let the researcher know you would like to be involved. 
 
A consent document is attached to this letter for the live education program.  The consent 
document contains additional information about my research, please sign the consent document 
and return it to me at the time of the live education program.   
 
If you choose to participate, you will be provided with a complimentary luncheon during the 
educational program. 
 
Sincerely, 
 
Lindsey Buzzeo 
Liberty University DNP/FNP Student 
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Collaborative Institutional Training Initiative Certificate 
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Appendix F 
Liberty University IRB Approval 
 
May 21, 2019 
Lindsey Buzzeo 
IRB Application 3817: Shingrix Education for Providers 
Dear Lindsey Buzzeo, 
The Liberty University Institutional Review Board has reviewed your application in accordance with the 
Office for Human Research Protections (OHRP) and Food and Drug Administration (FDA) regulations 
and finds your study does not classify as human subjects research. This means you may begin your 
research with the data safeguarding methods mentioned in your IRB application. 
Your study does not classify as human subjects research because evidence-based practice projects 
are considered quality improvement activities, which are not considered “research” according to 
45 CFR 46.102(d). 
Please note that this decision only applies to your current research application, and any changes to your 
protocol must be reported to the Liberty IRB for verification of continued non-human subjects research 
status. You may report these changes by submitting a new application to the IRB and referencing the 
above IRB Application number. 
If you have any questions about this determination or need assistance in identifying whether possible 
changes to your protocol would change your application’s status, please email us at irb@liberty.edu. 
Sincerely, 
 
G. Michele Baker, MA, CIP 
Administrative Chair of Institutional Research 
Research Ethics Office 
 
Liberty University | Training Champions for Christ since 1971  
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Appendix G 
Site IRB Approval Letter 
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Appendix H 
Demographic Survey 
 
1. How old are you? 
a. 20-30 years 
b. 31-40 years 
c. 41-50 years 
d. 51-60 years  
e. 60 years and older 
2. How many years have you been licensed as a provider? 
a. 0-3 years 
b. 4-7 years 
c. 8-11 years  
d. 12-15 years 
e. 16 years or more 
3. What is your primary area of practice? 
a. Primary care 
b. Family care 
c. Pediatrics 
d. Other specialties 
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4. Have you ever practiced in any of the following areas? (select all that apply) 
a. Primary care 
b. Family care 
c. Pediatrics 
d. Other specialties 
5. Have you attended an in-service education program on the shingrix vaccine in the past?  
a. Yes 
b. No 
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Appendix I 
Pretest and Posttest 
 
1. How does shingles typically manifest in a patient according to the Centers for Disease 
Control (CDC)? 
a. Unilateral vesicular lesions along a thoracic dermatome 
b. Disseminated papular lesions  
c. Localized nummular lesions  
d. Linear ulcerated lesions   
2. What age is an individual at risk to be diagnosed with Shingles? 
a. 40 years of age and older  
b. 50 years of age and older  
c. 60 years of age and older  
d. 70 years of age and older   
3. What is the average percentage of patients that have postherpetic neuralgia after a 
shingles diagnosis?  
a. 5-10% 
b. 11-15% 
c. 16-20% 
d. 21-25% 
4. The Shingrix vaccine is different from the Zostavax vaccine because it contains live 
attenuated herpes zoster.  
a. True 
b. False 
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5. What is the population age that is recommended to receive the Shingrix vaccination? 
a. 40 years of age and older 
b. 50 years of age and older  
c. 60 years of age and older  
d. 70 years of age and older  
6. How effective is Shingrix in preventing the disease? 
a. 90% 
b. 80% 
c. 70% 
d. 60%   
7. What are the contraindications for the Shingrix vaccine? (Select all that apply) 
a. Have ever had a high fever with the Shingrix vaccine  
b. Have received the Zostavax vaccine 
c. Have ever had a severe allergic reaction to the Shingrix vaccine  
d. Currently are diagnosed with Shingles 
e. Currently are taking antiviral medications  
8. What are common side effects associated with the vaccine? (Select all that apply) 
a.  Arm pain at the site of injection 
b. Muscle pain  
c. Headache 
d. Fever 
e. Abdominal pain and nausea 
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9. Administration is safe for individuals who are immunocompromised. 
a. True 
b. False 
10. Medicare Part D covers the Shingrix vaccine.  
a. True 
b. False 
11. Medicaid plans cover the Shingrix vaccine.  
a. True  
b. False 
12. Private insurances vary on their coverage of the Shingrix vaccine.  
a. True 
b. False  
13. How confident are you when discussing vaccine recommendations with your patients? 
a. Very confident 
b. Confident 
c. Slightly confident 
d. Not confident  
14. How likely are you to recommend the Shingrix vaccine to your patients? 
a. Very likely 
b. Likely  
c. Somewhat likely 
d. Not likely  
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15. How confident do you feel answering your patient’s questions about the vaccine? 
a. Very confident 
b. Confident 
c. Slightly confident 
d. Not confident  
16. How confident do you feel discussing the vaccine with a patient who has refused? 
a. Very confident 
b. Confident 
c. Slightly confident 
d. Not confident  
17. You have specific talking points when discussing the vaccine with patients who have 
refused the Shingrix vaccine? 
a. True 
b. False   
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Appendix J 
  
Patient Number Age Older than 50 
Years 
Inclusion Criteria: 
Annual Wellness 
Visit  
Exclusion Criteria: 
Contraindications for 
the Shingrix Vaccine 
Provider 
Recommended 
vaccine 
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Appendix K 
 
Provider Presentation 
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